



HU000028512T2

(19) **HU**(11) Lajstromszám: **E 028 512**(13) **T2****MAGYARORSZÁG**
Szellemi Tulajdon Nemzeti Hivatala**EURÓPAI SZABADALOM**
SZÖVEGÉNEK FORDÍTÁSA

(21) Magyar ügyszám: **E 06 822478**

(22) A bejelentés napja: **2006. 10. 27.**

(96) Az európai bejelentés bejelentési száma:
EP 20060822478

(97) Az európai bejelentés közzétételi adatai:
EP 1950307 A1 **2008. 07. 30.**

(97) Az európai szabadalom megadásának meghirdetési adatai:
EP 1950307 B1 **2015. 12. 23.**

(51) Int. Cl.: **C12N 158/67** (2006.01)
A61K 35/76 (2006.01)
A61K 38/00 (2006.01)
A61K 38/17 (2006.01)
A61K 48/00 (2006.01)
A61P 11/00 (2006.01)
C07K 14/47 (2006.01)
C12N 50/71 (2006.01)
C12N 5/10 (2006.01)
C12N 15/86 (2006.01)

(86) A nemzetközi (PCT) bejelentési szám:
PCT/JP 06/321517

(87) A nemzetközi közzétételi szám:
WO 07049752

(30) Elsőbbségi adatok: 2005313971 2005. 10. 28. JP	(73) Jogosult(ak): ID Pharma Co., Ltd., Ibaraki 300-2611 (JP)
(72) Feltaláló(k): MITOMO, Katsuyuki c/o ID Pharma Co., Ltd, Ibaraki 300-2611 (JP) INOUE, Makoto c/o ID Pharma Co., Ltd., Ibaraki 300-2611 (JP) IWASAKI, Hitoshi c/o ID Pharma Co., Ltd., Ibaraki 300-2611 (JP) HASEGAWA, Mamoru c/o ID Pharma Co., Ltd, Ibaraki 300-2611 (JP) ALTON, Eric W, London SW3 6LR (GB) GRIESENBACH, Uta, London SW3 6LR (GB)	(74) Képvisező: Danubia Szabadalmi és Jogi Iroda Kft., Budapest

(54) **Géntranszfer légúti epiteliális őssejtbe, RNS-vírus túskefehérjével pszeudotipizált lentivírusvektor alkalmazásával**

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(11) **EP 1 950 307 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 72, 73

(51) Int Cl.:
C12N 15/867 ^(2006.01) **A61K 35/76** ^(2015.01)
A61K 38/00 ^(2006.01) **A61K 48/00** ^(2006.01)
A61P 11/00 ^(2006.01) **C12N 5/10** ^(2006.01)
C12N 5/071 ^(2010.01) **C12N 15/86** ^(2006.01)
C07K 14/47 ^(2006.01) **A61K 38/17** ^(2006.01)

(48) Corrigendum issued on:
24.02.2016 Bulletin 2016/08

(86) International application number:
PCT/JP2006/321517

(45) Date of publication and mention
of the grant of the patent:
23.12.2015 Bulletin 2015/52

(87) International publication number:
WO 2007/049752 (03.05.2007 Gazette 2007/18)

(21) Application number: **06822478.1**

(22) Date of filing: **27.10.2006**

(54) **GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS SPIKE PROTEIN**

GENTRANSFER IN LUFTWEGEPITHELSTAMMZELLE UNTER VERWENDUNG EINES MIT RNA-VIRUS-SPIKE-PROTEIN PSEUDOTYPISIERTEN LENTIVIRUSVEKTORS

TRANSFERT D'UN GÈNE DANS DES CELLULES SOUCHES ÉPITHÉLIALES DES VOIES RESPIRATOIRES VIA UN VECTEUR LENTIVIRAL PSEUDOTYPE AVEC UNE PROTÉINE DE SPICULE DE VIRUS ARN

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: **28.10.2005 JP 2005313971**

(43) Date of publication of application:
30.07.2008 Bulletin 2008/31

(60) Divisional application:
15190286.3

(73) Proprietor: **ID Pharma Co., Ltd.**
Ibaraki 300-2611 (JP)

(72) Inventors:
• **MITOMO, Katsuyuki**
c/o ID Pharma Co., Ltd
Ibaraki 300-2611 (JP)
• **INOUE, Makoto**
c/o ID Pharma Co., Ltd.
Ibaraki 300-2611 (JP)

- **IWASAKI, Hitoshi**
c/o ID Pharma Co., Ltd.
Ibaraki 300-2611 (JP)
- **HASEGAWA, Mamoru**
c/o ID Pharma Co., Ltd
Ibaraki 300-2611 (JP)
- **ALTON, Eric W**
London SW3 6LR (GB)
- **GRIESENBACH, Uta**
London SW3 6LR (GB)

(74) Representative: **MacLean, Martin Robert**
Mathys & Squire LLP
The Shard
32 London Bridge Street
London SE1 9SG (GB)

(56) References cited:
WO-A1-01/92508 WO-A2-01/32898

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 950 307 B8

- MITOMO ET AL: "355. Towards Cystic Fibrosis and Airway Gene Therapy: Evaluation of EGFP Gene Expression in Murine Nasal Airways Mediated by Simian Immunodeficiency Virus Vectors Pseudotyped with Sendai Virus Glycoproteins F and HN" MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA, US LNKD-DOI:10.1006/MTHE.2002.0655, vol. 6, no. 2, 1 August 2002 (2002-08-01), pages 162-167, XP002956700 ISSN: 1525-0016
- KOBINGER G P ET AL: "Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo." NATURE BIOTECHNOLOGY MAR 2001 LNKD-PUBMED:11231554, vol. 19, no. 3, March 2001 (2001-03), pages 225-230, XP002593652 ISSN: 1087-0156
- SINN PATRICK L ET AL: "Persistent gene expression in mouse nasal epithelia following feline immunodeficiency virus-based vector gene transfer" JOURNAL OF VIROLOGY, vol. 79, no. 20, 1 October 2005 (2005-10-01), pages 12818-12827, XP002593653 ISSN: 0022-538X
- YONEMITSU Y ET AL: "Efficient gene transfer to airway epithelium using recombinant Sendai virus" NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US LNKD-DOI:10.1038/79463, vol. 18, no. 9, 1 September 2000 (2000-09-01), pages 970-973, XP002165781 ISSN: 1087-0156
- COPRENI E ET AL: "Lentivirus-mediated gene transfer to the respiratory epithelium: a promising approach to gene therapy of cystic fibrosis." GENE THERAPY OCT 2004 LNKD-PUBMED:15454960, vol. 11 Suppl 1, October 2004 (2004-10), pages S67-S75, XP002593654 ISSN: 0969-7128
- KLINK D ET AL: "Gene delivery systems-gene therapy vectors for cystic fibrosis" JOURNAL OF CYSTIC FIBROSIS, ELSEVIER LNKD-DOI:10.1016/J.JCF.2004.05.042, vol. 3, 1 August 2004 (2004-08-01), pages 203-212, XP004556460 ISSN: 1569-1993
- ASANO T ET AL: "Highly efficient gene transfer into primate embryonic stem cell with a simian lentivirus vector" MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA, US LNKD-DOI:10.1006/MTHE.2002.0655, vol. 6, no. 2, 1 August 2002 (2002-08-01), pages 162-167, XP002956700 ISSN: 1525-0016
- SCHNELL T ET AL: "DEVELOPMENT OF A SELF-INACTIVATING, MINIMAL LENTIVIRUS VECTOR BASEDON SIMIAN IMMUNODEFICIENCY VIRUS" HUMAN GENE THERAPY, MARY ANNLIEBERT, NEW YORK ,NY, US LNKD- DOI:10.1089/10430340050015905, vol. 11, 1 January 2000 (2000-01-01), pages 439-447, XP000916370 ISSN: 1043-0342
- KOBAYASHI M. ET AL: 'Pseudotyped lentivirus vectors derived from simian immunodeficiency virus SIVagm with envelope glycoproteins from paramyxovirus' JOURNAL OF VIROLOGY vol. 77, no. 4, 2003, pages 2607 - 2614, XP003011975
- MITOMO K. ET AL: 'Sendai Virus no Totanpakushitsu F, HN ni yotte Pseudotype-ka shita Saru Men'eki Fuzen Virus Vector wa Kikokei Soshiki ni Idenshi o Donyu dekuru' JAPANESE SOCIETY FOR VIROLOGY vol. 52, 2004, SHOROKUSHU, pages 377 - 3E16, XP003011976
- KOEHLER D.R. ET AL: 'Protection of Cfr knockout mice from acute lung infection by a helper-dependent adenoviral vector expressing Cfr in airway epithelia' PROC. NATL. ACAD. SCI. USA vol. 100, no. 26, 2003, pages 15364 - 15369, XP003011977

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification



(11) **EP 1 950 307 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
23.12.2015 Bulletin 2015/52

(21) Application number: **06822478.1**

(22) Date of filing: **27.10.2006**

(51) Int Cl.:
C12N 15/867 (2006.01) **A61K 35/76** (2015.01)
A61K 38/00 (2006.01) **A61K 48/00** (2006.01)
A61P 11/00 (2006.01) **C12N 5/10** (2006.01)
C12N 5/071 (2010.01) **C12N 15/86** (2006.01)
C07K 14/47 (2006.01) **A61K 38/17** (2006.01)

(86) International application number:
PCT/JP2006/321517

(87) International publication number:
WO 2007/049752 (03.05.2007 Gazette 2007/18)

(54) **GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS SPIKE PROTEIN**

GENTRANSFER IN LUFTWEGEPITHELSTAMMZELLE UNTER VERWENDUNG EINES MIT RNA-VIRUS-SPIKE-PROTEIN PSEUDOTYPISIERTEN LENTIVIRUSVEKTORS

TRANSFERT D'UN GÈNE DANS DES CELLULES SOUCHES ÉPITHÉLIALES DES VOIES RESPIRATOIRES VIA UN VECTEUR LENTIVIRAL PSEUDOTYPE AVEC UNE PROTÉINE DE SPICULE DE VIRUS ARN

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: **28.10.2005 JP 2005313971**

(43) Date of publication of application:
30.07.2008 Bulletin 2008/31

(60) Divisional application:
15190286.3

(73) Proprietor: **IP Pharma Co., Ltd.**
Ibaraki 300-2611 (JP)

(72) Inventors:
• **MITOMO, Katsuyuki**
c/o ID Pharma Co., Ltd
Ibaraki 300-2611 (JP)
• **INOUE, Makoto**
c/o DNAVEC CORPORATION
Ibaraki 300-2611 (JP)
• **IWASAKI, Hitoshi**
c/o DNAVEC CORPORATION
Ibaraki 300-2611 (JP)

• **HASEGAWA, Mamoru**
c/o ID Pharma Co., Ltd
Ibaraki 300-2611 (JP)
• **ALTON, Eric W**
London SW3 6LR (GB)
• **GRIESENBACH, Uta**
London SW3 6LR (GB)

(74) Representative: **MacLean, Martin Robert**
Mathys & Squire LLP
The Shard
32 London Bridge Street
London SE1 9SG (GB)

(56) References cited:
WO-A1-01/92508 WO-A2-01/32898

• **MITOMO ET AL: "355. Towards Cystic Fibrosis and Airway Gene Therapy: Evaluation of EGFP Gene Expression in Murine Nasal Airways Mediated by Simian Immunodeficiency Virus Vectors Pseudotyped with Sendai Virus Glycoproteins F and HN" MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 11, 15 August 2005 (2005-08-15), page 139, XP005015694 ISSN: 1525-0016**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 950 307 B1

- KOBINGER G P ET AL: "Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo." NATURE BIOTECHNOLOGY MAR 2001 LNKD- PUBMED: 11231554, vol. 19, no. 3, March 2001 (2001-03), pages 225-230, XP002593652 ISSN: 1087-0156
- SINN PATRICK L ET AL: "Persistent gene expression in mouse nasal epithelia following feline immunodeficiency virus-based vector gene transfer" JOURNAL OF VIROLOGY, vol. 79, no. 20, 1 October 2005 (2005-10-01), pages 12818-12827, XP002593653 ISSN: 0022-538X
- YONEMITSU Y ET AL: "Efficient gene transfer to airway epithelium using recombinant Sendai virus" NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US LNKD- DOI:10.1038/79463, vol. 18, no. 9, 1 September 2000 (2000-09-01), pages 970-973, XP002165781 ISSN: 1087-0156
- COPRENI E ET AL: "Lentivirus-mediated gene transfer to the respiratory epithelium: a promising approach to gene therapy of cystic fibrosis." GENE THERAPY OCT 2004 LNKD- PUBMED:15454960, vol. 11 Suppl 1, October 2004 (2004-10), pages S67-S75, XP002593654 ISSN: 0969-7128
- KLINK D ET AL: "Gene delivery systems-gene therapy vectors for cystic fibrosis" JOURNAL OF CYSTIC FIBROSIS, ELSEVIER LNKD- DOI: 10.1016/J.JCF.2004.05.042, vol. 3, 1 August 2004 (2004-08-01), pages 203-212, XP004556460 ISSN: 1569-1993
- ASANO T ET AL: "Highly efficient gene transfer into primate embryonic stem cell with a simian lentivirus vector" MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA, US LNKD- DOI:10.1006/MTHE.2002.0655, vol. 6, no. 2, 1 August 2002 (2002-08-01), pages 162-167, XP002956700 ISSN: 1525-0016
- SCHNELL T ET AL: "DEVELOPMENT OF A SELF-INACTIVATING, MINIMAL LENTIVIRUS VECTOR BASED ON SIMIAN IMMUNODEFICIENCY VIRUS" HUMAN GENE THERAPY, MARY ANN LIEBERT, NEW YORK, NY, US LNKD- DOI: 10.1089/10430340050015905, vol. 11, 1 January 2000 (2000-01-01), pages 439-447, XP000916370 ISSN: 1043-0342
- KOBAYASHI M. ET AL: 'Pseudotyped lentivirus vectors derived from simian immunodeficiency virus SIVagm with envelope glycoproteins from paramyxovirus' JOURNAL OF VIROLOGY vol. 77, no. 4, 2003, pages 2607 - 2614, XP003011975
- MITOMO K. ET AL: 'Sendai Virus no Totanpakushitsu F, HN ni yotte Pseudotype-ka shita Saru Men'eki Fuzen Virus Vector wa Kikokei Soshiki ni Idenshi o Donyu dekiru' JAPANESE SOCIETY FOR VIROLOGY vol. 52, 2004, SHOROKUSHU, pages 377 - 3E16, XP003011976
- KOEHLER D.R. ET AL: 'Protection of Cftr knockout mice from acute lung infection by a helper-dependent adenoviral vector expressing Cftr in airway epithelia' PROC. NATL. ACAD. SCI. USA vol. 100, no. 26, 2003, pages 15364 - 15369, XP003011977

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

DescriptionTechnical Field

5 **[0001]** The present invention relates to lentiviral vectors pseudotyped with RNA or DNA virus spike proteins for introducing genes into airway epithelial stem cells.

Background Art

10 **[0002]** Cystic fibrosis (CF) is the most common lethal autosomal recessive disorder among Caucasians. It is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. Such mutations prevent ion transfer across the airway epithelium, which leads to mucosal thickening and attachment of bacteria, ultimately causing the disorder. Therefore, airway epithelial cells are important targets for gene therapy.

15 **[0003]** For long-term expression of transgenes, it is important to introduce genes into airway epithelial progenitor cells including stem cells. "Stem cells" refers to undifferentiated cells which are multipotent and capable of self-renewal. In the case of the airway, stem cells are present near the ductal epithelia of the sub-mucosal glands and the basal cells of the basement membrane, and the ductal epithelium and the basal cells are protected from external toxins and injuries (see Non-patent Documents 1 and 2). Furthermore, in the mouse trachea, they are also reported to be scattered in the cartilage tissue (see Non-patent Document 1). In general, since epithelial stem cells are very few in number and exist
20 in isolated locations in the sub-mucosal glands, it is difficult to adopt the gene transfer approach and such. Furthermore, it is known that airway epithelial cells including stem cells are tissues where gene transfer is very difficult due to the presence of the mucin layer and mucus.

[0004] Moreover, airway epithelial cells have polarity, and the side in contact with outside air is referred to as apical side, and the celomic side is referred to as basolateral side. Since there are no virus receptors on the apical surface of
25 airway epithelial cells, there are hardly any vectors that can be efficiently transduced into intact airway epithelium. Receptors for most viruses including adenovirus are present on the basolateral side; therefore, preconditioning using EGTA, surfactants and such is necessary immediately before gene transfer. In the case of lentiviral vectors pseudotyped with vesicular stomatitis virus glycoprotein (VSV-G), for example, the epithelial surface must be preconditioned with a detergent to perform efficient transfection. However, clinically it may not be possible to use treatment with these chemical
30 substances.

[0005] Vectors for gene therapy and methods for their administration are being developed for genetic diseases of impaired respiratory system, such as cystic fibrosis. For gene transfer into airway epithelial cells, it is necessary to introduce the gene from the apical side of the epithelial cells by passing through the mucin layer and mucus. Invasion
35 of virus vectors that infect from the basolateral side is blocked by tight junctions present between epithelial cells. Accordingly, administration methods that disrupt these tight junctions by the combined use of a calcium chelating agent, EGTA, and various surfactants are employed. However, such treatments (preconditioning) are not desirable for clinical application to humans.

[0006] Since VSV-G receptors that are generally used for pseudotyping are present on the basolateral side of airway epithelial cells, treatment with lysophosphatidylcholine (LPC; a type of surfactant) is necessary for gene transfer. When
40 a mouse nasal cavity was infected with a VSV-G-pseudotyped HIV vector (carried gene; lacZ) after LPC treatment, the transgene expression was maintained for at least 92 days (see Non-patent Document 3). The result suggests the gene has been introduced into stem cells because epithelial cells lived three months. As an example of lentiviral vector pseudotyping without preconditioning, an envelope protein of the Ebola virus Zaire strain has been reported (see Non-patent Document 4). The carried gene LacZ was found to be maintained for 63 days in the mouse airway tissues.
45 Although the duration of this experiment was shorter than the survival time of epithelial cells, the gene was confirmed to be transferred into the sub-mucosal gland where the stem cells are said to exist.

[0007] The following documents are also known.

- 50 [Non-patent Document 1] Borthwick et al., Am J. Respir. Cell Mol. Biol., Vol. 24, pp.662-670, 2001
 [Non-patent Document 2] Engelhardt, Am J. Respir. Cell Mol. Biol., Vol. 24, pp.649-652, 2001
 [Non-patent Document 3] Limberis, et al., Human Gene Therapy, Vol. 13, pp.1961-1970, 2002
 [Non-patent Document 4] Kobinger et al., Nature Biotechnology, Vol. 19, pp.225-230, 2001
 [Non-patent Document 5] Alberto Auricchio et al., The Journal of Clinical Investigation, Vol. 110, Number 4,
 pp.499-504, 2002
 55 [Non-patent Document 6] John F. Engelhardt, The Journal of Clinical Investigation, Vol. 110, Number 4, pp.429-432,
 2002
 [Non-patent Document 7] Kobayashi M. et al., J. Virol. 77(4) : 2607-2614, 2003
 [Non-patent Document 8] Mitomo et al., Mol. Therapy 11 :139, 2005

Disclosure of the Invention

5 [Problems to be Solved by the Invention]

[0008] An objective of the present invention is to provide lentiviral vectors pseudotyped with RNA or DNA virus spike proteins for introducing genes into airway epithelial stem cells.

10 [Means for Solving the Problems]

[0009] The present inventors carried out dedicated research to solve the above-mentioned problems. Specifically, to develop vectors that can introduce genes into airway epithelial stem cells, vectors of a simian immunodeficiency virus (SIV), a type of lentivirus, were pseudotyped with envelope glycoproteins F and HN, which are spike proteins of Sendai virus, a type of RNA virus.

[0010] The airway epithelium is covered with mucus, and it has been difficult to transfer genes into airway epithelial cells and such with conventional techniques. For introducing genes into these cells, a method that physically removes the extracellular matrix such as mucus by washing had been tried. However, this method was cumbersome and posed the danger of tissue damage.

[0011] This time, the present inventors focused on the function of Sendai virus, a virus infecting the airway system, to efficiently transfect from the apical side airway epithelial cells that have not been preconditioned; developed vectors produced by pseudotyping a simian immunodeficiency virus vector with Sendai virus envelope glycoproteins F and HN; and for the first time, discovered methods of using these vectors to introduce genes into airway epithelial cells and airway stem cells.

[0012] Lentiviral vectors such as simian immunodeficiency virus vectors incorporate a carried gene into host genome by the action of an integrase. Therefore, if genes can be introduced into stem cells using a simian immunodeficiency virus vector pseudotyped with Sendai virus glycoproteins, the vectors will be useful for treating genetic diseases of the respiratory system, such as cystic fibrosis.

[0013] As described above, the present inventors developed vectors produced by pseudotyping simian immunodeficiency virus vectors with glycoproteins F and HN which are spike proteins of the airway-infecting Sendai virus; and developed methods of using these vectors for efficiently introducing genes into airway epithelial stem cells without preconditioning, from the apical side through the mucus layer. By using glycoproteins of airway-infecting viruses as envelope proteins, it became possible to introduce genes into airway epithelial cells as well as stem cells including progenitor cells. The technique for introducing genes into stem cells using the vectors of the present invention enables stable maintenance of gene expression, well beyond the survival time of epithelial cells.

[0014] Specifically, the present invention relates to lentiviral vectors pseudotyped with RNA or DNA virus spike proteins for introducing genes into airway epithelial stem cells. Accordingly, the present invention provides a recombinant SIV vector for use in treating cystic fibrosis by introducing a gene into an airway epithelial stem cell that has not been subjected to pretreatment or pre-conditioning treatment, wherein the vector (i) is pseudotyped with spike proteins of the Sendai virus envelope glycoproteins F and HN, and (ii) comprises a foreign gene in an expressible state, and further wherein said vector enables the integration of said foreign gene in said stem cell so as to provide long term foreign gene expression of at least 360 days

[0015] The invention further provides the use of a recombinant SIV vector in the manufacture of a medicament for treatment of a cystic fibrosis, wherein: (a) said vector is pseudotyped with spike proteins of the Sendai virus envelope glycoproteins F and HN and comprises a foreign gene in an expressible state and wherein said vector enables the integration of said foreign gene in an airway epithelial stem cell so as to provide long term foreign gene expression of at least 360 days; and (b) said medicament is for administration to airway epithelial stem cells.

In one embodiment, the recombinant SIV vector is derived from an agm strain.

The recombinant SIV vector may be a self-inactivating vector in which the promoter sequence for the 3' LTR U3 region is eliminated and/or substituted with another promoter sequence.

In one embodiment, the foreign gene is a gene encoding: (a) an inherent or acquired dysfunctional cystic fibrosis (CF)-causing factor; (b) an inherent or acquired dysfunctional CFTR protein; (c) a protein having a therapeutic effect on cystic fibrosis; (d) a CFTR protein that is needed for the treatment of cystic fibrosis; or (e) a CFTR protein, wherein expression of said CFTR protein supplements a deficient CFTR gene.

55 Also disclosed are the following:

[1] a lentiviral vector for introducing a gene into an airway epithelial stem cell, wherein the vector is pseudotyped with an RNA or DNA virus spike protein;

- [2] the lentiviral vector of [1], wherein the RNA virus is an RNA virus that infects an airway tissue;
- [3] the lentiviral vector of [1], wherein the RNA virus is a minus-strand RNA virus;
- [4] the lentiviral vector of [3], wherein the minus-strand RNA virus is a paramyxovirus
- [5] the lentiviral vector of [4], wherein the paramyxovirus is Sendai virus;
- 5 [6] the lentiviral vector of [3], wherein the minus-strand RNA virus is an orthomyxovirus;
- [7] the lentiviral vector of [6], wherein the orthomyxovirus is an influenza virus;
- [8] the lentiviral vector of [3], wherein the minus-strand RNA virus is a filovirus;
- [9] the lentiviral vector of [8], wherein the filovirus is Ebola hemorrhagic fever virus;
- [10] the lentiviral vector of [1], wherein the RNA virus is a plus-strand RNA virus;
- 10 [11] the lentiviral vector of [10], wherein the plus-strand RNA virus is a coronavirus;
- [12] the lentiviral vector of [11], wherein the coronavirus is SARS coronavirus;
- [13] the lentiviral vector of [1], wherein the DNA virus is a DNA virus that infects an airway tissue;
- [14] the lentiviral vector of [13], wherein the DNA virus is a baculovirus;
- [15] the lentiviral vector of any one of [1] to [14], wherein the lentiviral vector is a recombinant simian immunodeficiency virus vector;
- 15 [16] the lentiviral vector of [15], wherein the recombinant simian immunodeficiency virus vector is derived from an agm strain;
- [17] the lentiviral vector of [15] or [16], wherein the recombinant simian immunodeficiency virus vector is a self-inactivating vector;
- 20 [18] the lentiviral vector of any one of [1] to [14], wherein the lentiviral vector is an equine infectious anemia virus vector, human immunodeficiency virus-1 vector, human immunodeficiency virus-2 vector, or feline immunodeficiency virus vector;
- [19] the lentiviral vector of any one of [1] to [18], which carries a foreign gene in an expressible state;
- [20] the lentiviral vector of [19], wherein the foreign gene is a gene encoding a protein selected from the green fluorescent protein, beta-galactosidase, and luciferase;
- 25 [21] the lentiviral vector of [19], wherein the foreign gene is a gene encoding an inherent or acquired dysfunctional protein;
- [22] the lentiviral vector of [19], wherein the foreign gene is a gene encoding an inherent or acquired dysfunctional cystic fibrosis (CF)-causing factor;
- 30 [23] the lentiviral vector of [19], wherein the foreign gene is a gene encoding an inherent or acquired dysfunctional CFTR (cystic fibrosis transmembrane conductance regulator) protein;
- [24] the lentiviral vector of [19], wherein the foreign gene is a gene encoding a protein having a therapeutic effect on cystic fibrosis;
- [25] the lentiviral vector of [19], wherein the foreign gene is a gene encoding a protein that has become dysfunctional due to a genetic disease;
- 35 [26] the lentiviral vector of [25], wherein the protein that has become dysfunctional due to a genetic disease is a gene encoding CFTR;
- [27] a method for introducing a gene into an airway epithelial stem cell, which comprises the step of contacting an airway epithelial cell with the lentiviral vector of any one of [1] to [26];
- 40 [28] an airway epithelial stem cell into which the lentiviral vector of any one of [1] to [26] has been introduced;
- [29] an agent for transferring a gene into an airway epithelial stem cell, which comprises the lentiviral vector of any one of [1] to [26] as an active ingredient;
- [30] the agent of [29], wherein the lung is used as a production tissue to provide a protein necessary for disease treatment;
- 45 [31] a therapeutic agent for genetic respiratory disease, which comprises the lentiviral vector of any one of [1] to [26] as an active ingredient; and
- [32] the therapeutic agent of [31], wherein the genetic respiratory disease is cystic fibrosis.

50 **[0016]** Disclosed herein are methods for preventing or treating genetic respiratory diseases, which comprise the step of administering a lentiviral vector of the present invention to an individual. The present invention relates to prevention or treatment methods in which the above-mentioned genetic respiratory disease is cystic fibrosis. Furthermore, disclosed herein are uses of said lentiviral vectors for producing therapeutic agents for genetic respiratory diseases. The present invention also relates to the lentiviral vectors of the invention use for producing therapeutic agents, in which the above-mentioned genetic respiratory disease is cystic fibrosis.

55 Brief Description of the Drawings

[0017]

Fig. 1 depicts the amino acid sequence (SEQ ID NO: 1) of the boundary portion between the SIV cytoplasmic domain (underlined portion in italics) and the HN protein transmembrane domain (in italics) of a protein encoded by a cytoplasmic domain-substituted HN expression plasmid.

Fig. 2 depicts the amino acid sequence (SEQ ID NO: 2) of the boundary portion between the cytoplasmic domain (underlined portion in italics) and the HN protein transmembrane domain (in standard style) of a protein encoded by an SIV cytoplasmic domain-added HN expression plasmid.

Fig. 3 depicts the amino acid sequences (SEQ ID NOs: 3 to 5) of the boundary portion between the F protein transmembrane domain (in italics) and the F protein cytoplasmic domain (in standard style) of proteins encoded by cytoplasmic domain-deleted F expression plasmids.

Fig. 4 depicts the amino acid sequences (SEQ ID NOs: 6 to 8) of the boundary portion of the F protein transmembrane domain (in italics without underline), F protein cytoplasmic domain (in standard style), and 11 amino acids of the SIV cytoplasmic domain (SIV_{c11}) (underlined portion in italics) of proteins encoded by cytoplasmic domain-deleted F expression plasmid to which the SIV cytoplasmic domain has been added.

Fig. 5 shows photographs indicating long-term gene expression in the mouse nasal cavity by an F/HN-pseudotyped SIV vector of the present invention. The results of day 3 to day 360 are shown. The numbers in parentheses (x/x) indicate the number of mouse individuals showing gene expression/number of mouse individuals tested. When the numerical values are separated on the left and right, the left shows the number of individuals indicating strong GFP expression, and the right shows the number of mouse individuals used for analysis each day. The scale bar represents 5 mm.

Fig. 6 shows photographs indicating that excellent specific gene transfer was observed in mouse nasal cavity epithelium due to an F/HN-pseudotyped SIV vector of the present invention. The results of day 36 and day 50 are shown. The scale bar represents 0.5 mm.

Fig. 7 is a continuation of the photographs of Fig. 6. They show that expression was observed on days 160, 220, and 360, which surpass the survival time of the cells. The scale bar represents 0.5 mm.

Fig. 8 is a schematic diagram that depicts the movement of differentiated cells in the epithelial tissue when stem cells are present in their niches (right) and when stem cells are scattered around the epithelial cell basement membrane (left). SMG refers to sub-mucosal gland. The four plane views at the bottom show the apical surface of the airway epithelium. The lower two plane views depict the result after two cycles of stem cell division (approximately 180 days later). When the stem cells reach a certain proportion, the differentiated cells rapidly move laterally. Cell regeneration takes place in three-month intervals. In the figure, striped (shaded) circles indicate stem cells, open circles represent airway epithelial progenitor cells, grey circles represent airway epithelial cells in the process of differentiation, and filled circles represent differentiated airway epithelial cells.

Best Mode for Carrying Out the Invention

[0018] The present inventors constructed vectors pseudotyped with spike proteins of minus-strand RNA viruses by using a simian immunodeficiency virus (SIV) selected from lentiviruses expected to be used as a gene therapy vector. The simian immunodeficiency virus has various advantages such as high safety compared to the human immunodeficiency virus (HIV) conventionally used in the field of gene therapy. For example, simian immunodeficiency virus vectors pseudotyped with the F and HN proteins of Sendai virus, a minus-strand RNA virus, were constructed as described below in the Examples. Furthermore, foreign genes were successfully introduced into stem cells of the mouse nasal cavity by using these vectors.

[0019] More specifically, described herein are lentiviral vectors pseudotyped with RNA virus or DNA virus spike proteins (herein below, these vectors may be referred to as "-pseudotyped lentiviral vectors" or simply "vectors") for introducing genes into airway epithelial stem cells.

[0020] "Lentiviral vectors" as described herein are virus particles that contain a lentivirus-derived viral genome, lack the self-renewal ability, and have the ability to introduce a nucleic acid molecule into a host. Specifically, these vectors have a lentiviral backbone. The phrase "has a lentiviral backbone" means that the nucleic acid molecule included in the virus particles constituting the vectors is based on a lentiviral genome. For example, the lentiviral vectors of the present invention include vectors in which a nucleic acid molecule contained in virus particles contains a lentiviral genome-derived packaging signal sequence. Furthermore, "recombinant viral vectors" refers to viral vectors constructed by genetic recombination techniques. Viral vectors constructed using packaging cells and DNAs encoding a viral genome are called recombinant viral vectors.

[0021] "Lentiviruses" refers to retroviruses belonging to the lentivirus subfamily. Viruses such as the following are included as lentiviruses:

human immunodeficiency virus (HIV) (for example, HIV 1 or HIV2);
simian immunodeficiency virus (SIV);

feline immunodeficiency virus (FIV);
 Maedi-Visna-like virus (EV1);
 equine infectious anemia virus (EIAV); and
 caprine arthritis encephalitis virus (CAEV).

5
[0022] As described herein, lentiviral vectors derived from any strain and subtype can be used. For example, as HIV1, all major (M) subtypes (including A to J), N, and outliers (O) are included (Hu, D. J. et al., JAMA 1996; 275: 210-216; Zhu, T. et al., Nature 1998, 5; 391 (6667): 594-7; Simon, F. et al., Nat. Med. 1998, 4 (9): 1032-7). The present invention relates to lentiviral ventors derived from SIV.

10
[0023] The phrase "lentiviral vectors pseudotyped with RNA virus spike proteins" refers to lentiviral vectors containing RNA virus spike proteins. It also refers to lentiviral vectors carrying one or more RNA virus spike proteins that are not carried by the natural form of the lentiviral vectors. The phrase "lentiviral vectors pseudotyped with DNA virus spike proteins" refers to lentiviral vectors containing DNA virus spike proteins. It also refers to lentiviral vectors carrying one or more DNA virus spike proteins that are not carried by the natural form of the lentiviral vectors.

15
[0024] In the present invention, the term "airway epithelial stem cell" which becomes a target of gene transfer refers to a stem cell present in airway epithelial tissues. Stem cells are undifferentiated cells that are multipotent and have the self-renewal ability. Three types are known: hematopoietic stem cells, mesenchymal stem cells (bone marrow stroma cells: D. J. Prockop, Science, 276, 71-74, 1997), and stem cells present in tissues of various organs.

20
[0025] Furthermore, the term "airway epithelial tissues" refers to, for example, tissues of the nose, nasal cavity, pharynx, larynx, tracheae, bronchi, lungs and such. Preferred airway epithelial tissues in the present invention are the nasal cavity, tracheae, and lungs. Furthermore, airway epithelial stem cells of the present invention are not limited to stem cells present in the sub-mucosal glands. Specifically, airway epithelial stem cells can be defined as all hematopoietic stem cells, mesenchymal stem cells, and stem cells in various organ tissues that can differentiate into airway epithelial tissues.

25
[0026] The pseudotyped lentiviral vectors of the present invention have the function to introduce genes into airway epithelial stem cells. Specifically, RNA viruses or DNA viruses used for pseudotyping in the present invention preferably have the function to infect airway epithelial tissues.

30
[0027] As disclosed herein, the term "RNA virus" refers to a virus containing an RNA genome. RNA viruses are preferably viruses that synthesize RNAs during their lifecycle using RNAs as a template. RNA viruses may be desirable RNA viruses that replicate genomic RNAs in airway epithelial cells, and they may be wild-type viruses, or mutant viruses such as attenuated viruses, temperature-sensitive viruses and such. Furthermore, they may be natural viruses (naturally occurring viruses) or recombinant viruses. RNA viruses include single-stranded RNA viruses (including plus-strand RNA viruses and minus-strand RNA viruses) and double-stranded RNA viruses. They also include viruses with envelope (enveloped viruses) and viruses without envelope (non-enveloped viruses), but preferably, enveloped viruses are used. RNA viruses as disclosed herein specifically include viruses belonging to the following families:

- 35
Arenaviridae such as Lassa virus;
Orthomyxoviridae such as influenza virus;
Coronaviridae such as SARS coronavirus;
Togaviridae such as rubella virus;
 40
Paramyxoviridae such as mumps virus, measles virus, Sendai virus, and RS virus;
Picornaviridae such as poliovirus, Coxsackie virus, and echovirus;
Filoviridae such as Marburg virus and Ebola hemorrhagic fever virus;
Flaviviridae such as yellow fever virus, dengue fever virus, hepatitis C virus, and hepatitis G virus;
Bunyaviridae;
 45
Rhabdoviridae such as rabies virus; and
Reoviridae.

[0028] The term "plus-strand RNA viruses" refers to viruses that contain plus-strand RNAs as genome. Of them, SARS coronavirus (Severe Acute Respiratory

50
[0029] Syndrome virus (SARS virus) and new type coronaviruses) of *Coronaviridae* are preferably used in the present disclosure. Plus-strand RNA viruses include, for example, the following:

- 55
Coronaviridae such as SARS virus;
Caliciviridae such as norovirus;
Picornaviridae;
Astroviridae such as astrovirus;
Togaviridae;
Flaviviridae;

Retroviridae such as human immunodeficiency virus; and
Bunyaviridae.

[0030] Furthermore, the term "minus-strand RNA virus" as disclosed herein refers to a virus containing a minus strand (an antisense strand of a viral protein-encoding sense strand) RNA as genome. A minus-strand RNA is also referred to as a negative-strand RNA. The minus-strand RNA viruses used in the present disclosure particularly include single-stranded minus-strand RNA viruses (also referred to as non-segmented minus-strand RNA viruses). The term "single-stranded negative-strand RNA virus" refers to a virus containing a single-stranded negative-strand (i.e., minus-strand) RNA as genome.

[0031] The above-mentioned minus-strand RNA viruses include viruses belonging to *Paramyxoviridae* (including the genera *Paramyxovirus*, *Morbillivirus*, *Rubulavirus*, and *Pneumovirus*), *Rhabdoviridae* (including the genera *Vesiculovirus*, *Lyssavirus*, and *Ephemerovirus*), *Filoviridae* including Ebola hemorrhagic fever virus, *Orthomyxoviridae* (including Influenza viruses A, B, and C, and Thogoto-like viruses), *Bunyaviridae* (including the genera *Bunyavirus*, *Hantavirus*, *Nairovirus*, and *Phlebovirus*), *Arenaviridae* and the like.

[0032] Specific examples of minus-strand RNA viruses used in the present disclosure include Sendai virus, Newcastle disease virus, Mumps virus, Measles virus, Respiratory syncytial virus (RS virus), rinderpest virus, distemper virus, simian parainfluenza virus (SV5), and human parainfluenza viruses I, II, and III, which are *Paramyxoviridae* viruses; influenza virus belonging to *Orthomyxoviridae*; the vesicular stomatitis virus and Rabies virus belonging to *Rhabdoviridae*; and Ebola virus belonging to *Filoviridae*. Of them, Sendai virus, influenza viruses, and Ebola viruses are preferably used in the present disclosure. Sendai virus is used according to the present invention.

[0033] Sendai virus includes wild-type strain, mutant, laboratory-passaged strains, and artificially established strains. Defective viruses such as DI particles (J. Virol. 68, 8413-8417 (1994)), synthesized oligonucleotides and such may also be used as materials for producing pseudotyped lentiviral vectors of the present invention.

[0034] The "spike proteins" of the present invention may also be referred to as envelope proteins. Specifically, the term "spike proteins" refers to protruding proteins arranged on a virus envelope surface, which are virus glycoproteins and may exist as multimers. They play an indispensable role in the attachment and invasion of enveloped viruses into host cells. For example, the two types of spike proteins in Sendai virus are hemagglutinin-neuraminidase (HN) glycoprotein and fusion glycoprotein (F). In influenza virus, there are two types of spike proteins, hemagglutinin (trimer) (HA) and neuraminidase (tetramer) (NA). In SARS virus, spike glycoprotein exists as the spike protein. In the Ebola hemorrhagic fever virus Zaire strain, the EboZ envelope protein, a protruding protein of approximately 10 nm in length, exists as the spike protein.

[0035] Spike proteins as disclosed herein are not limited to the above-mentioned spike proteins such as HN, F, HA, NA, and EboZ; and for example, even if the names are different, proteins in other RNA viruses or DNA viruses that correspond to the above-mentioned spike proteins are also included. The present invention relates to the Sendai virus F and HN spike proteins. These spike proteins may be modified by one or more amino acid substitutions, deletions, insertions, and/or additions to natural proteins, so long as the functions of the original proteins are maintained. The number of amino acids that can be modified is not particularly limited; however, it is generally 50 amino acids or less, preferably 30 amino acids or less, and more preferably ten amino acids or less (for example, five amino acids or less, or three amino acids or less). The amino acid modifications are preferably conservative substitutions. The present disclosure also includes lentiviral vectors pseudotyped with proteins comprising such modified amino acids.

[0036] The pseudotyped lentiviral vectors of the present invention can be produced by having spike proteins present at the time of virus production. For example, by expressing spike in packaging cells through transfection of a spike expression vector or through induction of expression of spike genes incorporated into the host chromosomal DNA, virus particles produced from these cells become pseudotyped with the spike proteins.

[0037] Furthermore, the present disclosure relates to the pseudotyped lentiviral vectors in which the RNA viruses are paramyxoviruses.

[0038] Known examples of genes encoding viral proteins of paramyxoviruses are the NP, P, M, F, HN, and L genes. The "NP, P, M, F, HN, and L genes" refers to genes encoding the nucleocapsid, phospho-, matrix, fusion, hemagglutinin-neuraminidase, and large proteins, respectively. The genes of the viruses belonging to the paramyxovirus subfamily are generally described as listed below. In general, the NP gene may also be referred to as the "N gene".

Genus <i>Paramyxovirus</i>	NP P/C/V M F HN - L
Genus <i>Rubulavirus</i>	NP P/V M F HN (SH) L
Genus <i>Morbillivirus</i>	NP P/C/V M F H - L

[0039] For example, the nucleotide sequence of each gene in Sendai virus, which belongs to the genus *Paramyxovirus* of the family *Paramyxoviridae*, has accession numbers in the database as follows: M29343, M30202, M30203, M30204,

M51331, M55565, M69046, and X17218 for the NP gene; M30202, M30203, M30204, M55565, M69046, X00583, X17007, and X17008 for the P gene; D11446, K02742, M30202, M30203, M30204, M69046, U31956, X00584, and X53056 for the M gene; D00152, D11446, D17334, D17335, M30202, M30203, M30204, M69046, X00152, and X02131 for the F gene; D26475, M12397, M30202, M30203, M30204, M69046, X00586, X02808, and X56131 for the HN gene; and D00053, M30202, M30203, M30204, M69040, X00587, and X58886 for the L gene.

[0040] A lentiviral vector pseudotyped with a paramyxovirus envelope protein can be produced, for example, by preparing an inactivated paramyxovirus or a virosome containing an envelope protein of a paramyxovirus, and then fusing this with a lentivirus. Alternatively, it can be produced by expressing an expression vector for expression of the paramyxovirus envelope protein in a lentiviral packaging cell.

[0041] The present invention relates to the pseudotyped lentiviral vectors in which the paramyxovirus is Sendai virus.

[0042] The present disclosure also relates to the pseudotyped lentiviral vectors in which the minus-strand RNA viruses are orthomyxoviruses.

[0043] *Orthomyxoviridae* viruses include the genera *Influenzavirus A*, *Influenzavirus B*, *Influenzavirus C*, and *Thogotovirus*. An *Influenzavirus A* includes Influenza A virus (FLUAV), an *Influenzavirus B* includes Influenza B virus (FLUBV), an *Influenzavirus C* includes Influenza C virus (FLUCV), and a *Thogotovirus* includes *Thogoto virus* (THOV) and *Dhori virus* (DHOV).

[0044] Known examples of genes encoding viral proteins of orthomyxoviruses are the HA, NA, and M1 genes. The "HA, NA, and M1 genes" refers to genes encoding the hemagglutinin, neuraminidase, and matrix (membrane) proteins, respectively. The genes of viruses belonging to the family *Orthomyxoviridae* are generally described as listed below. In general, the HA gene may also be denoted as H, and the NA gene may be denoted as N.

Genus <i>Influenzavirus A</i>	PB2, PB1, PA, HA, NP, NA, M1+M2, NS1+NS2
Genus <i>Influenzavirus B</i>	PB2, PB1, PA, HA, NP, NA+NB, M1+M2, NS1+NS2
Genus <i>Influenzavirus C</i>	PB2, PB1, P3 (PA), HE (HA), NP, M, NS1+NS2
Genus <i>Thogotovirus</i>	PB2, PB1, PA, GP-75 (THOV), GP-64 (DHOV), NP, M

[0045] For example, the nucleotide sequences of envelope genes of Influenzavirus A virus belonging to the genus *Influenzavirus A* of *Orthomyxoviridae* have accession numbers in the database as follows: NC_002017 for the HA gene and NC_002018 for the NA gene.

[0046] The nucleotide sequences of envelope genes of Influenza B virus belonging to the genus *Influenzavirus B* have accession numbers as follows: NC_002207 for the HA gene and NC_002209 for the NA gene.

[0047] The nucleotide sequence of an envelope gene of Influenza C virus belonging to the genus *Influenzavirus C* has accession number NC_006310 for the HE (hemagglutinin-esterase precursor) gene in the database.

[0048] The nucleotide sequence of an envelope gene of Dhori virus belonging to the genus *Thogotovirus* has accession number NC_006506 for the GP-64 gene in the database.

[0049] Furthermore, the present disclosure relates to the pseudotyped lentiviral vectors in which the orthomyxoviruses are influenzaviruses.

[0050] The present disclosure also relates to the pseudotyped lentiviral vectors in which the minus-strand RNA viruses are filoviruses.

[0051] *Filoviridae* includes the genus Marburg-like viruses, and the genus Ebola-like viruses. The genus Marburg-like viruses includes Marburg viruses, and the genus Ebola-like viruses includes the Zaire strain, Reston strain, and Sudan strain of Ebola hemorrhagic fever virus. Any of the above-mentioned strains can be used as Ebola hemorrhagic fever virus in the present disclosure. Preferably the Zaire strain of Ebola hemorrhagic fever virus is used.

[0052] For example, the nucleotide sequences of genes encoding viral proteins of Ebola hemorrhagic fever virus in the database have accession numbers NC_002549, L11365, AF086833, AF272001, U28077, U31033, and AY142960.

[0053] Furthermore, the present disclosure relates to the pseudotyped lentiviral vectors in which the filovirus is Ebola hemorrhagic fever virus.

[0054] The present disclosure also relates to the pseudotyped lentiviral vectors in which the plus-strand RNA viruses are coronaviruses.

[0055] *Coronaviridae* includes the genus *Coronavirus* and the genus *Torovirus*. Examples of the genus *Coronavirus* include SARS virus, infectious bronchitis virus, human coronavirus, and murine hepatitis virus, and examples of the genus *Torovirus* include equine torovirus and human torovirus.

[0056] For example, the nucleotide sequences of genes encoding viral proteins of SARS virus in the database have accession numbers NP_828851 for a spike protein and NC_004718.

[0057] Furthermore, the present disclosure relates to the pseudotyped lentiviral vectors in which the coronavirus is SARS virus.

[0058] The present disclosure also relates to the pseudotyped lentiviral vectors in which the DNA viruses are baculo-

viruses. Since spike proteins of baculoviruses have structural similarities to spike proteins of influenza D virus such as Thogoto, it is suggested that baculoviruses can infect the airway epithelium (Sinn, P. L., Burnight, E. R., Hickey, M. A., Blissard, G. W., and McCray, P. B., Jr. Persistent gene expression in mouse nasal epithelia following feline immunodeficiency virus-based vector gene transfer. *J. Virol.* (2005) 79: 12818-12827). Baculoviruses include, for example, *Autographa californica*.

[0059] For example, when the minus-strand RNA viruses are paramyxoviruses, the lentiviral vectors pseudotyped with RNA virus or DNA virus spike proteins preferably comprise the HN protein and F protein. When the minus-strand RNA viruses are orthomyxoviruses, the vectors preferably comprise not only the HA protein but also the NA protein, the GP88 protein, or HE. When the RNA viruses are coronaviruses, the vectors preferably comprise the S protein. When the RNA viruses are filoviruses, the vectors preferably comprise envelope proteins.

[0060] In the present invention, it was demonstrated that pseudotyped simian immunodeficiency virus vectors containing the HN and F proteins of Sendai virus show high efficiency of gene transfer into airway epithelial stem cells. Specifically, lentiviral vectors of the present invention include pseudotyped simian immunodeficiency virus vectors containing the F and HN proteins. Furthermore, pseudotyped simian immunodeficiency virus vectors of the present invention may further contain the paramyxovirus M protein.

[0061] The simian immunodeficiency virus (SIV) was discovered as a monkey-derived HIV-like virus. Along with HIV, SIV forms the primate lentivirus group (E. Ido and M. Hayamizu, "Gene, Infection and Pathogenicity of Simian Immunodeficiency Virus", Protein, Nucleic acid and Enzyme, Vol.39, No.8, p.1425, 1994). This group is further divided into four subgroups:

- (1) the HIV-1 subgroup: containing HIV-1, the virus which causes human acquired immune deficiency syndrome (AIDS), and SIVcpz isolated from chimpanzees;
- (2) the HIV-2 subgroup: containing SIVsmm isolated from Sooty Mangabeys (*Cercocebus atys*), SIVmac isolated from rhesus monkeys (*Macaca mulatta*), and HIV-2, which is less pathogenic in humans (Jaffar, S. et al., *J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.*, 16(5), 327-32, 1997);
- (3) the SIVagm subgroup: represented by SIVagm isolated from African green monkeys (*Cercopithecus aethiops*); and
- (4) the SIVmnd subgroup: represented by SIVmnd isolated from Mandrills (*Papio sphinx*).

[0062] SIV in the present invention includes all strains and subtypes of SIV. Examples of isolated SIV strains include SIVagm, SIVcpz, SIVmac, SIVmnd, SIVsm, SIVsnm, and SIVsyk.

[0063] There are no reports of SIVagm and SIVmnd pathogenicity in natural hosts (Ohta, Y. et al., *Int. J. Cancer*, 15, 41(1), 115-22, 1988; Miura, T. et al., *J. Med. Primatol.*, 18 (3-4), 255-9, 1989; M. Hayamizu, *Nippon Rinsho*, 47, 1, 1989). In particular, reports of infection experiments suggest that the TYO-1 strain of the SIVagm virus is not pathogenic to cynomolgus monkeys (*Macaca fascicularis*) and rhesus monkeys (*Macaca mulatta*), in addition to its natural hosts (Ali, M. et al, *Gene Therapy*, 1 (6), 367-84, 1994; Honjo, S et al., *J. Med. Primatol.*, 19 (1), 9-20, 1990). There are no reports of SIVagm infection, pathogenesis or pathogenic activity in humans. In general, primate lentiviruses have strict species-specificity, and there are few reports of cross-species infection or pathogenesis from natural hosts. Where cross-species infection does occur, the frequency of disease onset is normally low, and the disease progress is slow (Novembre, F. J. et al., *J. Virol.*, 71(5), 4086-91, 1997). Accordingly, SIV derived from the agm strain are preferably used in the present invention. Furthermore, viral vectors based on the SIVagm TYO-1 strain are thought to be safer than vectors based on HIV-1 or other lentiviruses, and are thus preferred for use in the present invention.

[0064] The pseudotyped simian immunodeficiency virus vectors of the present invention may further contain envelope proteins derived from other viruses. For example, envelope proteins derived from viruses that infect human cells are preferred as such proteins. Such proteins include, but are not particularly limited to, retroviral amphotropic envelope proteins. For example, envelope proteins derived from the murine leukemia virus (MuLV) 4070A strain can be used as retroviral amphotropic envelope proteins. Alternatively, envelope proteins derived from MuLV 10A1 can also be used (for example, pCL-10A1 (Imgenex) (Naviaux, R. K. et al., *J. Virol.* 70: 5701-5705 (1996)). Other examples include the envelope glycoprotein (GP) of the Zaire strain of Ebola hemorrhagic fever virus and the spike envelope protein (S protein) of severe acute respiratory syndrome (SARS) virus identified as a new type of coronavirus. Examples of proteins from the *Herpesviridae* include the gB, gD, gH, and gp85 proteins of herpes simplex viruses, and the gp350 and gp220 proteins of EB virus. Proteins from the *Hepadnaviridae* include the S protein of hepatitis B virus.

[0065] The simian immunodeficiency virus vectors of the present invention may contain a portion of a genomic RNA sequence derived from another retrovirus. Also included in the simian immunodeficiency virus vectors of the present invention are vectors comprising a chimeric sequence, resulting from replacing a portion of the simian immunodeficiency virus genome with, for example, a portion of the genomic sequence of another lentivirus such as human immunodeficiency virus (HIV), feline immunodeficiency virus (FIV) (Poeschla, E. M. et al., *Nature Medicine*, 4 (3), 354-7, 1998) or caprine arthritis encephalitis virus (CAEV) (Mselli-Lakhal, L. et al., *Arch. Virol.*, 143 (4), 681-95, 1998).

[0066] In retroviruses, the LTR (long terminal repeat) may also be modified. The LTR is a retrovirus-specific sequence, which is present at both ends of the viral genome. The 5' LTR serves as a promoter, enhancing proviral mRNA transcription. Thus, it may be possible to enhance mRNA transcription of the gene transfer vector, improve packaging efficiency, and increase vector titer if the portion exhibiting the 5' LTR promoter activity in the gene transfer vector is substituted with another promoter having stronger promoter activity. Furthermore, for example, in the case of lentiviruses, the viral protein tat is known to enhance 5' LTR transcription activity, and therefore, substitution of the 5' LTR with a promoter independent of the tat protein will enable the exclusion of tat from the packaging vectors. After RNAs of viruses which have infected or invaded cells are reverse transcribed, the LTRs at both ends are linked to form a closed circular structure, viral integrase couples with the linkage site, and this structure is then integrated into cell chromosomes. The transcribed proviral mRNAs consist of the region ranging from the 5' LTR transcription initiation site to the 3' LTR polyA sequence located downstream. The 5' LTR promoter portion is not packaged in the virus. Thus, even if the promoter is replaced with another sequence, the portion integrated into target cell chromosomes is unchanged. Based on the facts described above, substitution of the 5' LTR promoter is thought to provide a safer vector with a higher titer. Thus, substitution of the promoter at the 5' end of a gene transfer vector can increase the titer of a packageable vector.

[0067] Safety can be improved in recombinant simian immunodeficiency virus vectors by preventing transcription of the full-length vector mRNA in target cells. This is achieved using a self-inactivating vector (SIN vector) prepared by partially eliminating the 3' LTR sequence. The lentivirus provirus that has invaded the target cell chromosomes, has its 5' end bound to the U3 portion of its 3' LTR. Thus, the U3 portion is located at the 5' end in the gene transfer vector, and from that point, the whole RNA of the gene transfer vector is transcribed. If there are lentiviruses or similar proteins in target cells, it is possible that the gene transfer vector may be re-packaged and infect other cells. There is also a possibility that the 3' LTR promoter may express host genes located at the 3' side of the viral genome (Rosenberg, N., Jolicoeur, P., *Retroviral Pathogenesis. Retroviruses.* Cold Spring Harbor Laboratory Press, 475-585, 1997). These events are already considered to be problems of retroviral vectors, and the SIN vector was developed as a way of overcoming these problems (Yu, S. F. et al., *Proc. Natl. Acad. Sci. U S A*, 83 (10), 3194-8, 1986). When the 3' LTR U3 portion is deleted from a gene transfer vector, target cells lack the promoters of 5' LTR and 3' LTR, thereby preventing the transcription of the full-length viral RNA and host genes. Furthermore, since only the genes of interest are transcribed from endogenous promoters, highly safe vectors capable of high expression can be expected. Such vectors are preferable in the present invention. SIN vectors can be constructed according to known methods.

[0068] One problem encountered in gene therapy using viral vectors that have the LTR sequence in their genome, including retroviral vectors, is a gradual decrease in expression of an introduced gene. One factor behind this may be that when such a vector is integrated into the host genome, a host mechanism methylates the LTR to suppress expression of the introduced gene (Challita, P. M. and Kohn, D. B., *Proc. Natl. Acad. Sci. USA* 91: 2567, 1994). One advantage of SIN vectors is that LTR methylation hardly reduces gene expression level. This is because the vector loses most of the LTR sequence upon integration into the host genome. An SIN vector prepared by substituting another promoter sequence for the 3' LTR U3 region of a gene transfer vector, was found to maintain a stable expression for more than two months after introduction into primate ES cells (WO 02/101057). Thus, an SIN vector designed to self-inactivate by the modification of the LTR U3 region is especially suitable in the present invention.

[0069] Examples of lentiviral vectors of the present disclosure other than the above-mentioned simian immunodeficiency virus vectors include equine infectious anemia virus (EIAV) vectors, human immunodeficiency virus (HIV, for example HIV1 or HIV2) vectors, and feline immunodeficiency virus (FIV) vectors.

[0070] A risk that has been pointed out concerning lentivirus vectors such as HIV vectors is that if the host genome already has an HIV provirus, recombination may occur between a foreign vector and the endogenous provirus, leading to production of replication-competent viruses. This is predicted to become a serious problem in the future, when HIV vectors are used in HIV patients. The SIV vectors used in the present invention have low sequence homology with HIV, and are replication-incompetent because 80.6% of the virus-derived sequence has been removed from the vectors. Thus, these vectors do hardly pose this risk and are safer than other lentiviral vectors. Accordingly, of these lentiviral vectors, simian immunodeficiency virus (SIV) vectors are used in the present invention.

[0071] The preferred SIV vectors of the present invention are replication-incompetent viruses from which 40% or more, more preferably 50% or more, still more preferably 60% or more, even more preferably 70% or more, and most preferably 80% or more of the sequence derived from the original SIV genome has been removed.

[0072] Retroviruses can be produced by transcribing in host cells gene transfer vector DNAs which contain a packaging signal and forming virus particles in the presence of gag, pol and envelope proteins. The packaging signal sequence encoded by the gene transfer vector DNAs should preferably be sufficient in length to maintain the structure formed by the sequence. However, in order to suppress the frequency of wild-type virus formation, which occurs due to recombination of the vector DNA packaging signal and the packaging vector supplying the gag and pol proteins, it is also necessary to keep sequence overlapping between these vector sequences to a minimum. Therefore, when it comes to the construction of the gene transfer vector DNAs, it is preferable to use a sequence which is as short as possible and yet still contains the sequence essential for packaging, to ensure packaging efficiency and safety.

[0073] For example, in the case of the SIVagm-derived packaging vector, the type of virus from which the signal to be used is derived may be limited to SIV, because HIV vectors are not packaged. However, an SIV-derived gene transfer vector is also packageable when an HIV-derived packaging vector is used. Thus, the frequency of recombinant virus formation can be reduced if vector particles are formed by combining a gene transfer vector and packaging vector, where
5 each vector is derived from a different type of lentivirus. SIV vectors thus produced are also included in vectors of this invention. In such cases, it is preferable to use combinations of primate lentiviruses (for example, HIV and SIV).

[0074] In a preferred gene transfer vector DNA, the gag protein has been modified such that it is not expressed. Viral gag protein may be detected by a living body as a foreign substance, and thus as a potential antigen. Alternatively, the protein may affect cellular functions. To prevent gag protein expression, nucleotides downstream of the gag start codon
10 can be added or deleted, introducing modifications which will cause a frameshift. It is also preferable to delete portions of the coding region of the gag protein. The 5' portion of the coding region of the gag protein is known to be essential for virus packaging. Thus, in a gene transfer vector, it is preferable that the C-terminal side of the gag protein-coding region has been deleted. It is preferable to delete as large a portion of the gag coding region as possible, so long as the deletion does not considerably affect the packaging efficiency. It is also preferable to replace the start codon (ATG) of
15 the gag protein with a codon other than ATG. The replacement codon can be selected appropriately so as not to greatly affect the packaging efficiency. A viral vector can be produced by introducing the constructed gene transfer vector DNA, which comprises the packaging signal, into appropriate packaging cells. The viral vector produced can be recovered from, for example, the culture supernatant of packaging cells.

[0075] There is no limitation on the type of packaging cell, as long as the cell line is generally used in viral production. When used for human gene therapy, a human- or monkey-derived cell is suitable. Human cell lines that can be used as packaging cells include, for example, 293 cells, 293T cells, 293EBNA cells, SW480 cells, u87MG cells, HOS cells, C8166 cells, MT-4 cells, Molt-4 cells, HeLa cells, HT1080 cells, and TE671 cells. Monkey cell lines include, for example, COS1 cells, COS7 cells, CV-1 cells, and BMT10 cells.

[0076] The type of foreign gene to be carried by the pseudotyped lentiviral vectors of the present invention is not limited. Such genes include nucleic acids which encode proteins, and those which do not encode proteins, for example, antisense nucleic acids and ribozymes. The genes may have a natural or an artificially designed sequence. Artificial proteins include fusion proteins with other proteins, dominant-negative proteins (including soluble receptor molecules and membrane-bound dominant negative receptors), truncated cell-adhesion molecules, and soluble cell-surface molecules.

[0077] The present inventors confirmed that pseudotyped lentiviral vectors of the present invention express foreign genes for a long period of time in airway epithelial cells including airway epithelial stem cells and airway epithelial progenitor cells. Specifically, the pseudotyped lentiviral vectors of the present invention have the ability to express foreign genes in airway epithelial cells for at least 90 days or more, and more preferably 360 days or more.

[0078] Foreign genes in the present invention may be marker genes to assess the efficiency of gene transfer, stability of expression, and so on. Marker genes include genes that encode green fluorescent protein (hereinafter also referred to as "GFP"), beta-galactosidase, and luciferase. The GFP-encoding gene is particularly preferable.

[0079] Furthermore, foreign genes in the present invention may be genes encoding an inherent or acquired dysfunctional protein. Herein, the phrase "inherent dysfunctional" refers to being innately dysfunctional due to genetic factors, and the phrase "acquired dysfunctional" refers to being dysfunctional due to environmental factors after birth.

[0080] For example, in the case of cystic fibrosis (CF), examples include genes encoding inherent or acquired dysfunctional cystic fibrosis-causing factors (proteins), and preferably genes encoding inherent or acquired dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) proteins.

[0081] Alternatively, examples of foreign genes in the present invention include genes encoding proteins having therapeutic effects on cystic fibrosis.

[0082] Or otherwise, examples of foreign genes in the present invention may be genes encoding proteins that have become dysfunctional due to a genetic disease. An example is a gene encoding the CFTR protein.

[0083] The pseudotyped lentiviral vectors of the present invention can be purified to become substantially pure. The phrase "substantially pure" means that the pseudotyped lentiviral vectors contain substantially no replicable virus other than the lentivirus. The purification can be achieved using known purification and separation methods such as filtration, centrifugation, and column purification. For example, a vector can be precipitated and concentrated by filtering a vector solution with a 0.45- μ m filter, and then centrifuging it at 42500 x g at 4°C for 90 minutes. If necessary, the pseudotyped lentiviral vectors of the present invention can be prepared as compositions by appropriately combining with desired pharmaceutically acceptable carriers or vehicle. The term "pharmaceutically acceptable carrier" refers to a material that can be administered in conjunction with the vector and does not significantly inhibit vector-mediated gene transfer.
55 Specifically, the vector can be appropriately combined with, for example, sterilized water, physiological saline, culture medium, serum, and phosphate buffered saline (PBS). The vector can also be combined with a stabilizer, biocide, and such. Compositions containing a pseudotyped lentiviral vector of the present invention are useful as reagents or pharmaceuticals. For example; compositions of the present invention can be used as reagents for gene transfer into airway

stem cells, or as pharmaceuticals for gene therapy of various diseases such as genetic diseases.

[0084] A nucleic acid carried by a pseudotyped lentiviral vector of the present invention can be introduced into airway epithelial stem cells by contacting this vector with airway epithelial cells of primates including humans. The present invention relates to methods for introducing genes into airway epithelial stem cells, which comprise the step of contacting airway epithelial cells with the vectors of the present invention. The present disclosure also relates to uses of lentiviral vectors pseudotyped with RNA or DNA virus spike proteins for introducing genes into airway epithelial stem cells, with the invention relating to the use of particular lentiviral vectors pseudotyped with RNA virus spike proteins as described herein. The airway epithelial stem cells targeted for gene introduction are not particularly limited, and for example, bone marrow-derived stem cells including mesenchymal stem cells that may differentiate into the desired simian or human airway epithelium can also be used as airway epithelial stem cells.

[0085] Monkey-derived airway epithelial stem cells which are targets of gene transfer by the pseudotyped lentiviral vectors of the present invention are not particularly limited, but examples include marmoset airway epithelial stem cells, rhesus monkey airway epithelial stem cells, and cynomolgus monkey airway epithelial stem cells.

[0086] The procedure for transferring genes into airway epithelial stem cells using a pseudotyped lentiviral vector of the present invention is carried out by a method comprising the step of contacting airway epithelial cells with the vector. For example, as described below in the Examples, the vector can be contacted with the cells by administering it to the nasal cavity using a catheter.

[0087] Pseudotyped lentiviral vectors of the present invention have the advantage of yielding extremely high gene transfer efficiency even without pretreatment such as washing the cell surface before contacting the vector.

[0088] The present disclosure also relates to airway epithelial stem cells introduced with lentiviral vectors of the present invention pseudotyped with RNA or DNA virus spike proteins, and cells produced by proliferation and/or differentiation of these cells.

[0089] Airway epithelial stem cells to which genes have been introduced by pseudotyped lentiviral vectors of the present invention, and cells, tissues, organs and such differentiated from these airway stem cells are useful for assaying and screening for various types of pharmaceutical agents. Through gene transfer into airway epithelial stem cells, for example, pharmaceutical agents or genes for carrying out specific differentiation of tissues or cells, and particularly preferably tissues or cells derived from primates, can be evaluated for their effects or screened for.

[0090] The present disclosure also encompasses airway epithelial stem cells into which pseudotyped lentiviral vectors of the present invention have been introduced, and differentiated cells and tissues that have differentiated from the airway epithelial stem cells. The differentiated cells and tissues can be identified based on marker expression and morphological characteristics specific to the tissues or cells.

[0091] Furthermore, by using the pseudotyped lentiviral vectors of the present invention, genes can be efficiently introduced into and expressed in airway epithelial stem cells for a long time. Specifically, the present invention relates to agents for transferring genes into airway epithelial stem cells, which comprise as an active ingredient a pseudotyped lentiviral vector of the present invention. For example, when using the above-mentioned gene transfer agents for airway epithelial stem cells, tissues or organs such as lungs may be used as a production tissue to provide proteins needed for disease treatment.

[0092] Furthermore, since the pseudotyped lentiviral vectors of the present invention can introduce genes into airway epithelial stem cells for long periods of time as described above, they can be applied to gene therapy of genetic respiratory diseases of primates including humans. Specifically, the present disclosure relates to therapeutic agents for genetic respiratory diseases which comprise a pseudotyped virus vector of the present invention as an active ingredient.

[0093] The present disclosure also relates to methods for preventing or treating genetic respiratory diseases, which comprise the step of administering a pseudotyped lentiviral vector of the present invention to individuals (for example, patients), with the present invention relating to cystic fibrosis. The "individuals" in the preventive or therapeutic methods of the present invention are preferably, for example, primates including humans, but they may be non-human animals. In the present invention, "administering to individuals" can be carried out, for example, by contacting a pseudotyped lentiviral vector of the present invention with airway epithelial cells. As described below in the Examples, the contact can be accomplished by administering the vector to the nasal cavity using a catheter.

[0094] Furthermore, the present disclosure relates to uses of pseudotyped lentiviral vectors of the present invention for producing therapeutic agents for genetic respiratory diseases. The targeted genetic respiratory diseases of the present invention is cystic fibrosis.

[0095] Cells, tissues, and organs differentiated from airway epithelial stem cells into which genes have been introduced may also be used for disease treatment. For example, for diseases that develop due to deficiency or lack of a gene, treatment that supplements the deficient gene and the lack of systemically circulating enzymes, growth factors and such may be performed by introducing the gene into a chromosome of airway stem cells and transplanting these cells into the body. Such diseases are not particularly limited. Furthermore, in organ transplantation-related gene therapy, a histocompatible antigen of a non-human animal donor may be converted into a human type. Accordingly, applications that increase the success rate of xenotransplantation can be performed.

[0096] When the airway epithelial stem cells into which a gene has been introduced using a pseudotyped lentiviral vector of this invention are monkey-derived, the airway epithelial stem cells can be transplanted into disease model monkeys to provide a system useful as a treatment model of human disease. Many disease model monkeys are known for various human diseases. For example, model monkeys for human Parkinson's disease can be produced artificially; many naturally diabetic monkeys are bred as accurate models of human diabetes; and SIV infection in monkeys is well known to serve as an accurate model of HIV infection in humans. For such diseases, a system where simian airway epithelial stem cells are transplanted into disease model monkeys as a preclinical test, prior to the clinical application of human airway epithelial stem cells, is exceedingly useful.

10 Examples

[0097] Herein below, the present invention will be specifically described with reference to the Examples, but it is not to be construed as being limited thereto.

15 [Example 1] Construction of Sendai virus envelope protein expression plasmids

(1) Construction of cytoplasmic domain-substituted HN expression plasmid

[0098] An HN expression plasmid was constructed, where the cytoplasmic domain of the HN protein was substituted with the cytoplasmic domain of the SIV envelope protein (Fig. 1). After annealing three sets of synthetic oligonucleotides (Xho+Xma/Xma-Xho, Xma+131/135-Xma, 132+Bam/Bam-136), they were incorporated in turn into the XhoI-BamHI site of pBluescript KS+. A purified synthetic oligonucleotide-linked fragment obtained by digesting the aforementioned recombinant plasmid with XhoI and DraIII and a purified fragment comprising the 3' side of the HN protein obtained by digesting the HN protein expression plasmid pCAGGS-HN with DraIII and Bsu36I were incorporated into the XhoI-Bsu36I site of pCAGGS (Gene, vol. 108, pp.193-200, 1991). The plasmid obtained by the above-mentioned method was used as the SIV cytoplasmic domain-substituted HN expression plasmid pCAGGS-SIVct/HN.

(2) Construction of SIV cytoplasmic domain-added HN expression plasmid

[0099] An HN expression plasmid was constructed, where the cytoplasmic domain of SIV envelope protein was added to the HN protein (Fig. 2). A region containing the cytoplasmic domain of SIV envelope protein and a portion of the HN protein was amplified by PCR using primers FSIVhn and RhnSIV, and using as a template the above-mentioned cytoplasmic domain-substituted HN protein expression plasmid. After the amplified fragment was digested with XhoI and Accl, the fragment was incorporated into the XhoI-AccI site of the pBluescript KS+ (Stratagene) prepared in (1) above, into which the three sets of synthetic oligonucleotides had been inserted, to replace with the fragment containing the cytoplasmic domain of SIV envelope. A purified synthetic oligonucleotide-linked fragment obtained by digesting the aforementioned recombinant plasmid with XhoI and DraIII and a fragment comprising the 3' side of the HN protein obtained by digesting the HN protein expression plasmid pCAGGS-HN with DraIII and Bsu36I were incorporated into the XhoI-Bsu36I site of pCAGGS (Gene, vol. 108, pp.193-200, 1991). The plasmid obtained by the above-mentioned method was used as the SIV cytoplasmic domain-added HN expression plasmid pCAGGS-SIVct+HN.

(3) Construction of cytoplasmic domain-deleted F protein expression plasmid

[0100] F protein expression plasmids were constructed, each of which contained the first 27, 14, or 4 residues from the 5' end of the cytoplasmic domain amino acids of F protein and thus lacked 15, 28, or 38 amino acid residues, respectively (Fig. 3). Each of the fragments lacking 15, 28, and 38 amino acids, respectively, was amplified by PCR using pairs of primers, XhFF and NotF1650, NotF1611 and NotF1581, and using as a template the plasmid pBluescript KS+/SmaI/F, in which the entire region for the F protein had been inserted into the SmaI site of pBluescript KS+ (Stratagene). The amplified fragments were digested with XhoI and NotI, and then each was inserted into the XhoI/NotI site of the plasmid that had been constructed from pCAGGS (Gene, vol.108, pp.193-200, 1991) by inserting an XhoI/NotI linker into the EcoRI site to construct plasmids (15 amino acid deletion: pCAGGS-Fct27; 28 amino acid deletion: pCAGGS-Fct14; 38 amino acid deletion: pCAGGS-Fct4). pCAGGS-Fct4 was used as an SIV vector for pseudotyping.

(4) Construction of cytoplasmic domain-deleted F protein expression plasmid to which the SIV cytoplasmic domain was added

[0101] Plasmids were constructed (Fig. 4) by adding the first 11 amino acids from 5' end of the SIV cytoplasmic domain (SIVct11) to cytoplasmic domain-deleted F protein expression plasmids (the numbers of amino acids in the cytoplasmic

domain of F protein are the same as those in the plasmids prepared in (3) above). Fragments corresponding to the above-described three types lacking the amino acids but containing the SIV cytoplasmic domain added were amplified by PCR using the pairs of primers XhFF and SA-F1650, and SA-F1611 and SA-F1581, and using as a template the plasmid pBluescript KS+/SmaI/F, in which the entire region for the F protein had been inserted into the SmaI site of pBluescript KS+ (Stratagene). The amplified fragments were digested with XhoI and NotI, and then each was inserted into the XhoI-NotI site of the plasmid that had been constructed from pCAGGS (Gene, vol.108, pp.193-200, 1991) by inserting an XhoI/NotI linker into the EcoRI site to construct plasmids (SIVct11 addition + 15 amino acid deletion: pCAGGS-Fct27/SIVct11; SIVct11 addition + 28 amino acid deletion: pCAGGS-Fct14/SIVct11; and SIVct11 addition + 38 amino acid deletion: pCAGGS-Fct4/SIVct11).

[0102] The nucleotide sequences of primers used in the Examples are listed below.

FSIVhn: 5'-GAGACTCGAGATGTGGTCTGAGTAAAAATCAGG-3' (SEQ ID NO: 9) RhnSIV:

5'-AGAGGTAGACCAGTACGAGTCACGTTTGCCCTATCACCATCCCTAACCTCTGTC
CATAAAC-3' (SEQ ID NO: 10)

XhFF: 5'-CCGCTCGAGCATGACAGCATATATCCAGAGA-3' (SEQ ID NO: 11)

NotF1650: 5'-ATAGTTTAGCGGCCGCTCATCTGATCTTCGGCTCTAATGT-3' (SEQ ID NO: 12)

NotF1611: 5'-ATAGTTTAGCGGCCGCTCAACGGTCATCTGGATTACCCAT-3' (SEQ ID NO: 13)

NotF1581: 5'-ATAGTTTAGCGGCCGCTCACCTTCTGAGTCTATAAAGCAC-3' (SEQ ID NO: 14)

SA-F1650:

5'-ATAGTTTAGCGGCCGCTATGGAGATAGAGGAACATATCCCTGCCTAACCTTCTGA
TCTTCGGCTCTAATGT-3' (SEQ ID NO: 15)

SA-F1611:

5'-ATAGTTTAGCGGCCGCTATGGAGATAGAGGAACATATCCCTGCCTAACCTACGGT
CATCTGGATTACCCAT-3' (SEQ ID NO: 16)

SA-F1581:

5'-ATAGTTTAGCGGCCGCTATGGAGATAGAGGAACATATCCCTGCCTAACCTCCTTC
TGAGTCTATAAAGCAC-3' (SEQ ID NO: 17).

[0103] As a result, while pseudotyping of SIV with naturally-occurring envelope proteins was impossible, fusion of the cytoplasmic domain (F) and modification by hemagglutinin-neuraminidase (HN) enabled efficient pseudotyping. An SeV-F/HN pseudotyped SIV vector containing the GFP gene was produced by transient transfection in 293T cells, and this was concentrated by centrifugation using techniques generally used for VSG-G pseudotyped vectors.

[Example 2] Gene transfer into mouse nasal cavity epithelial cells using the F/HN pseudotyped SIV vector

[0104] An F/HN pseudotyped SIV vector carrying eGFP was administered using a thin catheter to the mouse nasal cavity, the left nostril, without preconditioning (n = 3, 4 x 10⁸ TU per animal; 100 μl). The duration of expression of the transgenes was day 3 to day 360, and anatomical analysis of the mouse nasal cavity sections was performed according to the method of Mery *et al.* (Mery *et al.* Toxicol. Pathol. Vol. 22, p.353-372, 1994). GFP expression was evaluated in the nasal cavity sections located 1 to 4 mm (sections corresponding to distances of 1, 2, 3, and 4 mm) from the tip of the mouse nasal bone.

[0105] As a result, without preconditioning in airway epithelial cells, efficient transfection and continuous GFP expression was observed for at least 160 days. Expression of eGFP was found to be maintained even on day 220 and day 360. Since the survival time of mouse nasal cavity epithelial cells is 90 days or less (Borthwick *et al.* Am. J. Respir. Cell. Mol. Biol. Vol. 24, pp. 662-670, 2001), these results suggests as indirect evidence that the gene has been introduced into stem cells of the nasal cavity airway tissue (Figs. 5 to 7).

[0106] Furthermore, as shown in Fig. 8, stem cells stay in their niches when the stem cells are present in niches such

as the submucosal gland (right) and when the stem cells are scattered around the epithelial cell basal membrane (left), but it is known that differentiated cells move (lateral movement) in the epithelial tissues to switch places with cells whose life has ended (J. M. W. Slack Science Vol. 287, p.1431-1433, 2000). Therefore, GFP-positive cells were found scattered throughout the nasal cavity even on day 160, day 220, and day 360. If differentiated cells do not move, the differentiated epithelial cells should be found gathered around the stem cells. The results of the experiment suggest the possibility of the above-mentioned lateral movement.

Industrial Applicability

[0107] The present inventors have provided for the first time recombinant simian immunodeficiency virus vectors pseudotyped with envelope glycoproteins F/HN of Sendai virus, a minus-strand RNA virus, for introducing genes into airway epithelial stem cells. By using these vectors, a gene can be introduced into airway epithelial stem cells efficiently for a long time, and the vectors are considered to be very valuable for treating genetic respiratory diseases such as cystic fibrosis. By maintaining a foreign gene in an expressible state in vectors of the present invention, where the foreign gene is, for example, a gene encoding an inherent or acquired dysfunctional protein (such as cystic fibrosis-causing factor) or a gene encoding a protein that has become dysfunctional due to a genetic disease, the vectors may become very useful for treating the above-mentioned diseases.

SEQUENCE LISTING

[0108]

<110> DNAVEC CORPORATION

<120> Gene transfer into respiratory epithelium stem cells using lentivirus vectors pseudotyped by spike proteins of RNA virus or DNA virus

<130> D4-A0510P

<150> JP 2005-313971

<151> 2005-10-28

<160> 17

<170> PatentIn version 3.3

<210> 1

<211> 54

<212> PRT

<213> Artificial

<220>

<223> artificially synthesized sequence

<400> 1

Trp Ser Glu Leu Lys Ile Arg Ser Asn Asp Gly Gly Glu Gly Pro Glu
1 5 10 15

Asp Ala Asn Asp Pro Arg Gly Lys Gly Val Gln His Ile His Ile Gln
20 25 30

Pro Ser Leu Pro Val Tyr Gly Gln Arg Val Arg Val Arg Trp Leu Leu
35 40 45

Ile Leu Ser Phe Thr Gln
50

EP 1 950 307 B1

<210> 2
<211> 54
<212> PRT
<213> Artificial

5

<220>
<223> artificially synthesized sequence

<400> 2

10

Trp Ser Glu Leu Lys Ile Arg Ser Asn Asp Gly Gly Glu Gly Pro Glu
1 5 10 15

15

Asp Ala Asn Asp Pro Arg Gly Lys Gly Val Gln His Ile His Ile Gln
20 25 30

Pro Ser Leu Pro Val Tyr Gly Gln Arg Val Arg Val Arg Asp Gly Asp
35 40 45

20

Arg Gly Lys Arg Asp Ser
50

<210> 3
<211> 15
<212> PRT
<213> Artificial

25

<220>
<223> artificially synthesized sequence

30

<400> 3

Val Val Ile Ile Val Ile Ile Ile Val Leu Tyr Arg Leu Arg Arg
1 5 10 15

35

<210> 4
<211> 25
<212> PRT
<213> Artificial

40

<220>
<223> artificially synthesized sequence

<400> 4

45

Val Val Ile Ile Val Ile Ile Ile Val Leu Tyr Arg Leu Arg Arg Ser
1 5 10 15

50

Met Leu Met Gly Asn Pro Asp Asp Arg
20 25

<210> 5
<211> 38
<212> PRT
<213> Artificial

55

<220>
<223> artificially synthesized sequence

EP 1 950 307 B1

<400> 5

5 Val Val Ile Ile Val Ile Ile Ile Val Leu Tyr Arg Leu Arg Arg Ser
1 5 10 15
Met Leu Met Gly Asn Pro Asp Asp Arg Ile Pro Arg Asp Thr Tyr Thr
20 25 30
10 Leu Glu Pro Lys Ile Arg
35

<210> 6

<211> 26

<212> PRT

15 <213> Artificial

<220>

<223> artificially synthesized sequence

20 <400> 6

25 Val Val Ile Ile Val Ile Ile Ile Val Leu Tyr Arg Leu Arg Arg Arg
1 5 10 15
25 Val Arg Gln Gly Tyr Val Pro Leu Ser Pro
20 25
30

<210> 7

<211> 36

<212> PRT

35 <213> Artificial

<220>

<223> artificially synthesized sequence

40 <400> 7

45 Val Val Ile Ile Val Ile Ile Ile Val Leu Tyr Arg Leu Arg Arg Ser
1 5 10 15
Met Leu Met Gly Asn Pro Asp Asp Arg Arg Val Arg Gln Gly Tyr Val
20 25 30
Pro Leu Ser Pro
35
50

<210> 8

<211> 49

<212> PRT

55 <213> Artificial

<220>

<223> artificially synthesized sequence

<400> 8

EP 1 950 307 B1

Val Val Ile Ile Val Ile Ile Ile Val Leu Tyr Arg Leu Arg Arg Ser
1 5 10 15

5 Met Leu Met Gly Asn Pro Asp Asp Arg Ile Pro Arg Asp Thr Tyr Thr
20 25 30

Leu Glu Pro Lys Ile Arg Arg Val Arg Gln Gly Tyr Val Pro Leu Ser
35 40 45

10 Pro

<210> 9
<211> 34
<212> DNA
15 <213> Artificial

<220>
<223> an artificially synthesized primer sequence

20 <400> 9
gagactcgag atgtggtctg agttaaaaat cagg 34

<210> 10
<211> 63
25 <212> DNA
<213> Artificial

<220>
<223> an artificially synthesized primer sequence

30 <400> 10
agaggtagac cagtacgagt cacgtttgcc cctatcacca tccctaacc tctgtccata 60

35 aac 63

<210> 11
<211> 31
<212> DNA
40 <213> Artificial

<220>
<223> an artificially synthesized primer sequence

45 <400> 11
ccgctcgagc atgacagcat atatccagag a 31

<210> 12
<211> 40
50 <212> DNA
<213> Artificial

<220>
<223> an artificially synthesized primer sequence

55 <400> 12
atagtttagc ggccgctcat ctgatcttcg gctctaattg 40

EP 1 950 307 B1

<210> 13
<211> 40
<212> DNA
<213> Artificial
5
<220>
<223> an artificially synthesized primer sequence

<400> 13
10 atagtttagc ggccgctcaa cggcatctg gattacccat 40

<210> 14
<211> 40
<212> DNA
15 <213> Artificial

<220>
<223> an artificially synthesized primer sequence

<400> 14
20 atagtttagc ggccgctcac ctctgagtc tataaagcac 40

<210> 15
<211> 73
25 <212> DNA
<213> Artificial

<220>
<223> an artificially synthesized primer sequence
30
<400> 15

atagtttagc ggccgcctat ggagatagag gaacatatcc ctgcctaacc cttctgatct 60
35 tcggctctaa tgt 73

<210> 16
<211> 73
40 <212> DNA
<213> Artificial

<220>
<223> an artificially synthesized primer sequence
45
<400> 16

atagtttagc ggccgcctat ggagatagag gaacatatcc ctgcctaacc ctacgggcat 60
50 ctggattacc cat 73

<210> 17
<211> 73
55 <212> DNA
<213> Artificial

<220>

<223> an artificially synthesized primer sequence

<400> 17

5 atagtttagc ggccgcctat ggagatagag gaacatatcc ctgcctaacc ctcccttctga 60
gtctataaag cac 73

10

Claims

- 15 1. A recombinant SIV vector for use in treating cystic fibrosis by introducing a gene into an airway epithelial stem cell that has not been subjected to pretreatment or pre-conditioning treatment, wherein the vector (i) is pseudotyped with spike proteins of the Sendai virus envelope glycoproteins F and HN, and (ii) comprises a foreign gene in an expressible state, and further wherein said vector enables the integration of said foreign gene in said stem cell so as to provide long term foreign gene expression of at least 360 days.
- 20 2. Use of a recombinant SIV vector in the manufacture of a medicament for treatment of a cystic fibrosis, wherein:
- (a) said vector is pseudotyped with spike proteins of the Sendai virus envelope glycoproteins F and HN and comprises a foreign gene in an expressible state and wherein said vector enables the integration of said foreign gene in an airway epithelial stem cell so as to provide long term foreign gene expression of at least 360 days; and
- 25 (b) said medicament is for administration to airway epithelial stem cells.
3. The vector of claim 1 or the use of claim 2, wherein the recombinant SIV vector is derived from an agm strain.
4. The vector or use of claim 3, wherein the recombinant SIV vector is a self-inactivating vector in which the promoter sequence for the 3' LTR U3 region is eliminated and/or substituted with another promoter sequence.
- 30 5. The vector of claim 1, 3 or 4 or the use of anyone of claims 2 to 4, wherein the foreign gene is a gene encoding:
- (a) an inherent or acquired dysfunctional cystic fibrosis (CF)-causing factor;
- (b) an inherent or acquired dysfunctional CFTR protein;
- 35 (c) a protein having a therapeutic effect on cystic fibrosis;
- (d) a CFTR protein that is needed for the treatment of cystic fibrosis; or
- (e) a CFTR protein, wherein expression of said CFTR protein supplements a deficient CFTR gene.

40

Patentansprüche

- 45 1. Rekombinanter SIV-Vektor zur Verwendung bei der Behandlung von zystischer Fibrose durch Einführen eines Gens in eine epitheliale Luftwegsstammzelle, die keiner Vorbehandlung oder Vorkonditionierung unterzogen wurde, wobei der Vektor (i) mit Spike-Proteinen der Sendai-Virus-Hüllglycoproteine F und HN pseudotypisiert ist und (ii) ein Fremdgen in einem exprimierbaren Zustand umfasst und ferner wobei der genannte Vektor die Integration des genannten Fremdgens in die genannte Stammzelle ermöglicht, um eine langfristige Fremdgenexpression von mindestens 360 Tagen bereitzustellen.
- 50 2. Verwendung eines rekombinanten SIV-Vektors bei der Herstellung eines Medikaments zur Behandlung von zystischer Fibrose, wobei:
- (a) der genannte Vektor mit Spike-Proteinen der Sendai-Virus-Hüllglycoproteine F und HN pseudotypisiert ist und ein Fremdgen in einem exprimierbaren Zustand umfasst und wobei der genannte Vektor die Integration des genannten Fremdgens in eine epitheliale Luftwegsstammzelle ermöglicht, um eine langfristige Fremdgenexpression von mindestens 360 Tagen bereitzustellen; und
- 55 (b) das genannte Medikament für die Verabreichung an epitheliale Luftwegsstammzellen bestimmt ist.
3. Vektor nach Anspruch 1 oder Verwendung von Anspruch 2, wobei der rekombinante SIV-Vektor von einem AGM-

Stamm abgeleitet ist.

4. Vektor oder Verwendung nach Anspruch 3, wobei der rekombinante SIV-Vektor ein selbst-inaktivierender Vektor ist, bei dem die Promotorsequenz für die Region 3' LTR U3 beseitigt und/oder mit einer anderen Promotorsequenz substituiert ist.

5. Vektor nach Anspruch 1, 3 oder 4 oder Verwendung nach einem der Ansprüche 2 bis 4, wobei das Fremdgen ein Gen ist, das Folgendes codiert:

- (a) einen inhärenten oder erworbenen dysfunktionalen zystischen Fibrose (CF - Cystic Fibrosis) verursachenden Faktor;
- (b) ein inhärentes oder erworbenes dysfunktionales CFTR-Protein;
- (c) ein Protein, das eine therapeutische Wirkung auf zystische Fibrose aufweist;
- (d) ein CFTR-Protein, das zur Behandlung von zystischer Fibrose benötigt wird; oder
- (e) ein CFTR-Protein, wobei die Expression des genannten CFTR-Proteins ein mangelhaftes CFTR-Gen ergänzt.

Revendications

1. Vektor SIV rekombinant destiné à une utilisation dans le traitement de la mucoviscidose par introduction d'un gène dans une cellule souche épithéliale des voies respiratoires qui n'a pas fait l'objet d'un prétraitement ni d'un traitement de préconditionnement, le vecteur (i) étant pseudotypé avec des protéines de spicule des glycoprotéines F et HN de l'enveloppe du virus Sendai, et (ii) comprenant un gène étranger dans un état exprimable, et en outre ledit vecteur permettant l'intégration dudit gène étranger dans ladite cellule souche de façon à assurer une expression à long terme du gène étranger pendant au moins 360 jours.

2. Utilisation d'un vecteur SIV rekombinant dans la fabrication d'un médicament destiné au traitement d'une mucoviscidose, dans laquelle :

- (a) ledit vecteur est pseudotypé avec des protéines de spicule des glycoprotéines F et HN de l'enveloppe du virus Sendai, et comprend un gène étranger dans un état exprimable, et dans laquelle ledit vecteur permet l'intégration dudit gène étranger dans une cellule souche épithéliale des voies respiratoires de façon à assurer une expression à long terme du gène étranger pendant au moins 360 jours ; et
- (b) ledit médicament étant destiné à une administration sur des cellules souches épithéliales des voies respiratoires.

3. Vecteur selon la revendication 1 ou utilisation selon la revendication 2, ledit vecteur SIV rekombinant étant dérivé d'une souche agm.

4. Vecteur ou utilisation selon la revendication 3, ledit vecteur SIV rekombinant étant un vecteur auto-inactivant dans lequel la séquence promoteur pour la région U3 de la LTR 3' est éliminée et/ou substituée avec une autre séquence promoteur.

5. Vecteur selon la revendication 1, 3 ou 4 ou utilisation selon l'une quelconque des revendications 2 à 4, le gène étranger étant un gène codant pour :

- (a) un facteur dysfonctionnel inhérent ou acquis causant la mucoviscidose ;
- (b) une protéine CFTR dysfonctionnelle inhérente ou acquise ;
- (c) une protéine ayant un effet thérapeutique sur la mucoviscidose ;
- (d) une protéine CFTR qui est nécessaire pour le traitement de la mucoviscidose ; ou
- (e) une protéine CFTR, l'expression de ladite protéine CFTR supplémentant un gène CFTR déficient.

FIG. 1

SIV_{ct}/HN WSELKIRSNDGGEGPEDANDPRGKGVQHIHIQPSLPVYGQRVVR WLLILSFTQ

(SEQ ID NO: 1)

xxx: SIV CYTOPLASMIC DOMAIN

xxx: HN PROTEIN TRANSMEMBRANE DOMAIN

FIG. 2

SIVct+HN WSELKIRSNDGGEGPEDANDPRGKGVQHIHIQPSLPVYQQRVVR DGDRGKRDS
(SEQ ID NO: 2)

XXX: SIV CYTOPLASMIC DOMAIN

XXX: HN PROTEIN CYTOPLASMIC DOMAIN

FIG. 3

F_{ct 4} **VIIIVIIIIVLYRLRR** (SEQ ID NO: 3)
4

F_{ct14} **VIIIVIIIIVLYRLRRSMLGNPDDR** (SEQ ID NO: 4)
14

F_{ct27} **VIIIVIIIIVLYRLRRSMLGNPDDRIPRDTYITLEPKIR**
27
(SEQ ID NO: 5)

XXX: F PROTEIN TRANSMEMBRANE DOMAIN

XXX: F PROTEIN CYTOPLASMIC DOMAIN

FIG. 4

$F_{ct\ 4}/SIV_{ct11}$ *WVIIVIIIVLYRLRR RVRQGYVPLSP* (SEQ ID NO: 6)
 F_{ct14}/SIV_{ct11} *WVIIVIIIVLYRLRRSMLMGNPDDR RVRQGYVPLSP* (SEQ ID NO: 7)
 F_{ct27}/SIV_{ct11} *WVIIVIIIVLYRLRRSMLMGNPDDRIPRDTYTLPEPKIR RVRQGYVPLSP*
(SEQ ID NO: 8)

xxx: F PROTEIN TRANSMEMBRANE DOMAIN

xxx: F PROTEIN CYTOPLASMIC DOMAIN

xxx: 11 AMINO ACIDS OF SIV CYTOPLASMIC DOMAIN (SIV_{ct11})

FIG. 5




FIG. 6




FIG. 7





FIG. 8



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 0192508 A1 [0007]
- EP 1291419 A [0007]
- WO 02101057 A [0068]
- JP 2005313971 A [0108]

Non-patent literature cited in the description

- **BORTHWICK et al.** *Am J. Respir. Cell Mol. Biol.*, 2001, vol. 24, 662-670 [0007]
- **ENGELHARDT.** *Am J. Respir. Cell Mol. Biol.*, 2001, vol. 24, 649-652 [0007]
- **LIMBERIS et al.** *Human Gene Therapy*, 2002, vol. 13, 1961-1970 [0007]
- **KOBINGER et al.** *Nature Biotechnology*, 2001, vol. 19, 225-230 [0007]
- **ALBERTO AURICCHIO et al.** *The Journal of Clinical Investigation*, 2002, vol. 110 (4), 499-504 [0007]
- **JOHN F. ENGELHARDT.** *The Journal of Clinical Investigation*, 2002, vol. 110 (4), 429-432 [0007]
- **KOBAYASHI M. et al.** *J. Virol.*, 2003, vol. 77 (4), 2607-2614 [0007]
- **MITOMO et al.** *Mol. Therapy*, 2005, vol. 11, 139 [0007]
- **HU, D. J. et al.** *JAMA*, 1996, vol. 275, 210-216 [0022]
- **ZHU, T. et al.** *Nature*, May 1998, vol. 391 (6667), 594-7 [0022]
- **SIMON, F. et al.** *Nat. Med.*, 1998, vol. 4 (9), 1032-7 [0022]
- **D. J. PROCKOP.** *Science*, 1997, vol. 276, 71-74 [0024]
- *J. Virol.*, 1994, vol. 68, 8413-8417 [0033]
- DATABASE. M29343 [0039]
- DATABASE. M30202 [0039]
- DATABASE. M30203 [0039]
- DATABASE. M30204 [0039]
- DATABASE. M51331 [0039]
- DATABASE. M55565 [0039]
- DATABASE. M69046 [0039]
- DATABASE. X17218 [0039]
- DATABASE. X00583 [0039]
- DATABASE. X17007 [0039]
- DATABASE. X17008 [0039]
- DATABASE. D11446 [0039]
- DATABASE. K02742 [0039]
- DATABASE. U31956 [0039]
- DATABASE. X00584 [0039]
- DATABASE. X53056 [0039]
- DATABASE. D00152 [0039]
- DATABASE. D17334 [0039]
- DATABASE. D17335 [0039]
- DATABASE. X00152 [0039]
- DATABASE. X02131 [0039]
- DATABASE. D26475 [0039]
- DATABASE. M12397 [0039]
- DATABASE. X00586 [0039]
- DATABASE. X02808 [0039]
- DATABASE. X56131 [0039]
- DATABASE. D00053 [0039]
- DATABASE. M69040 [0039]
- DATABASE. X00587 [0039]
- DATABASE. X58886 [0039]
- DATABASE. NP_828851 [0056]
- DATABASE. NC_004718 [0056]
- **SINN, P. L. ; BURNIGHT, E. R. ; HICKEY, M. A. ; BLISSARD, G. W. ; MCCRAY, P. B. Jr.** Persistent gene expression in mouse nasal epithelia following feline immunodeficiency virus-based vector gene transfer. *J. Virol.*, 2005, vol. 79, 12818-12827 [0058]
- **E. IDO ; M. HAYAMIZU.** Gene, Infection and Pathogenicity of Simian Immunodeficiency Virus. *Protein, Nucleic acid and Enzyme*, 1994, vol. 39 (8), 1425 [0061]
- **JAFFAR, S. et al.** *J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.*, 1997, vol. 16 (5), 327-32 [0061]
- **OHTA, Y. et al.** *Int. J. Cancer*, 1988, vol. 15, 41 (1), 115-22 [0063]
- **MIURA, T. et al.** *J. Med. Primatol.*, 1989, vol. 18(3-4), 255-9 [0063]
- **M. HAYAMIZU.** *Nippon Rinsho*, 1989, vol. 47 (1) [0063]
- **ALI, M. et al.** *Gene Therapy*, 1994, vol. 1 (6), 367-84 [0063]
- **HONJO, S et al.** *J. Med. Primatol.*, 1990, vol. 19 (1), 9-20 [0063]
- **NOVEMBRE, F. J. et al.** *J. Virol.*, 1997, vol. 71 (5), 4086-91 [0063]
- **NAVIAUX, R. K. et al.** *J. Virol.*, 1996, vol. 70, 5701-5705 [0064]
- **POESCHLA, E. M. et al.** *Nature Medicine*, 1998, vol. 4 (3), 354-7 [0065]
- **MSELLI-LAKHAL, L. et al.** *Arch. Virol.*, 1998, vol. 143 (4), 681-95 [0065]

EP 1 950 307 B1

- **ROSENBERG, N. ; JOLICOEUR, P.** Retroviral Pathogenesis. Retroviruses. Cold Spring Harbor Laboratory Press, 1997, 475-585 **[0067]**
- **YU, S. F. et al.** *Proc. Natl. Acad. Sci.*, 1986, vol. 83 (10), 3194-8 **[0067]**
- **CHALLITA, P. M. ; KOHN, D. B.** *Proc. Natl. Acad. Sci.*, 1994, vol. 91, 2567 **[0068]**
- *Gene*, 1991, vol. 108, 193-200 **[0098] [0099] [0100] [0101]**
- **MERY et al.** *Toxicol. Pathol.*, 1994, vol. 22, 353-372 **[0104]**
- **BORTHWICK et al.** *J. Respir. Cell. Mol. Biol.*, 2001, vol. 24, 662-670 **[0105]**
- *J. M. W. Slack Science*, 2000, vol. 287, 1431-1433 **[0106]**

Szabadalmi igénypontok

1. Rekombináns SIV-vektor cisztás fibrózis kezelésében történő alkalmazásra, amely kezelés egy gén olyan légúti epiteliális őssejtbe juttatása útján történik, amelyet nem vetettek alá előkezelésnek vagy előkondicionáló kezelésnek, ahol a vektor (i) a Sendai vírus F és HN burok-glikoproteinjei tüskefehérjéivel („spike protein”) pszeudotipizálva van, és (ii) idegen gént tartalmaz expresszálnak állapotban, valamint ahol a vektor lehetővé teszi az idegen gén beépülését az őssejtbe, miáltal biztosítja az idegen gén legalább 360 napig tartó, hosszútávú expresszióját.

2. Rekombináns SIV-vektor alkalmazása cisztás fibrózis kezelésére szolgáló gyógyszer előállításában, ahol:

(a) a vektor a Sendai vírus F és HN burok-glikoproteinjei tüskefehérjéivel pszeudotipizálva van és idegen gént tartalmaz expresszálnak állapotban, valamint a vektor lehetővé teszi az idegen gén beépülését légúti epiteliális őssejtbe, miáltal biztosítja az idegen gén legalább 360 napig tartó, hosszútávú expresszióját, és

(b) a gyógyszer légúti epiteliális őssejteknek történő beadásra szolgál.

3. Az 1. igénypont szerinti vektor vagy a 2. igénypont szerinti alkalmazás, ahol a rekombináns SIV-vektor agm törzsből származik.

4. A 3. igénypont szerinti vektor vagy alkalmazás, ahol a rekombináns SIV-vektor önmagát inaktíváló vektor, ahol a 3' LTR U3 régió promóter-szekvenciája eliminálva van és/vagy másik promóter-szekvenciával van helyettesítve.

5. Az 1., 3. vagy 4. igénypont szerinti vektor vagy a 2-4. igénypontok bármelyike szerinti alkalmazás, ahol az idegen gén a következők bármelyikét kódoló gén:

(a) inherens vagy szerzett, diszfunkcionális cisztás fibrózist (CF) okozó faktor,

(b) inherens vagy szerzett, diszfunkcionális CFTR-fehérje,

(c) fehérje, amelynek terápiás hatása van cisztás fibrózisban,

(d) CFTR-fehérje, amely szükséges cisztás fibrózis kezeléséhez, és

(e) CFTR-fehérje, ahol a CFTR-fehérje expressziója hibás CFTR-gént szupplementál.

A meghatalmazott:

DANUBIA

Szabadalmi és jogi Iroda Kft.

Dr. Fethő Árpád

szabadalmi ügyvivő